证券代码：871970 证券简称：大禹生物 公告编号：2023-001 山西大禹生物工程股份有限公司 稳定股价措施实施结果公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 2022 年 7 月 22 日，山西大禹生物工程股份有限公司（以下简称"公司"） 发布了《山西大禹生物工程股份有限公司关于实施稳定股价方案的公告》。 一、 股份回购情况 （2）自公司股票在北交所上市之日起 3 个月内，公司启动稳定股价具体方 案 的实施期间内，公司股票收盘价连续 5 个交易日高于本次发行价格时； （3）各相关主体在连续 12 个月内购买股份的数量或用于购买股份的资金 金额已达到上限； （4）资金使用完毕。 2、本次触发稳定股价措施终止条件的具体情形 为维护公司股价的稳定，保护投资者的利益，公司于 2022 年 8 月 9 日至 2023 年 2 月 8 日对公司股票进行了回购，实际回购股数 559,600 股，使用资金总额 5,105,602.57 元（不含印花税、佣金等交易费用）。 （一） 本次股份回购计划主要内 ...

Financial Performance - Net profit attributable to shareholders decreased by 20.80% to CNY 11,731,517.27 for the year-to-date period[15] - Operating income for the year-to-date period decreased by 13.63% to CNY 96,125,595.93 compared to the same period last year[15] - Cash flow from operating activities decreased by 47.85% to CNY 9,041,300.56 compared to the same period last year[15] - Operating income for Q3 2022 increased by 8.95% to CNY 36,725,823.02 compared to Q3 2021[15] - Total operating revenue for Q3 2022 reached ¥36,725,823.02, an increase from ¥33,708,486.57 in Q3 2021, representing an increase of approximately 8.9% year-over-year[49] - Net profit for Q3 2022 was ¥3,887,300.91, up from ¥3,360,055.59 in Q3 2021, reflecting a growth of approximately 15.7% year-over-year[51] - The company’s total comprehensive income for the first nine months of 2022 was CNY 13,238,039, compared to CNY 15,830,795 in the same period of 2021[56] Assets and Liabilities - Total assets increased by 36.94% to CNY 406,038,834.29 compared to the end of the previous year[15] - Total current assets increased to CNY 131,543,220.47 as of September 30, 2022, up from CNY 86,677,798.07 on December 31, 2021, representing a growth of approximately 51.7%[41] - Non-current assets totaled CNY 274,495,613.82 as of September 30, 2022, up from CNY 209,825,087.39 on December 31, 2021, reflecting a growth of approximately 30.8%[42] - Total liabilities decreased to CNY 51,117,193.01 as of September 30, 2022, down from CNY 83,252,251.30 on December 31, 2021, a reduction of approximately 38.6%[43] - The total liabilities amounted to ¥50,769,042.72, while total equity reached ¥357,672,867.35, indicating a strong equity position relative to liabilities[47] Shareholder Information - The total number of ordinary shares at the end of the period was 55,960,000, with 14,228 shareholders[24] - The largest shareholder, Yan Heping, holds 26,623,000 shares, representing 47.58% of total shares[26] - The company plans to repurchase between 279,800 and 559,600 shares at a maximum price of 10 CNY per share, with a total estimated repurchase fund of 2.798 million to 5.596 million CNY[34] - As of September 30, 2022, the company had repurchased 213,000 shares, accounting for 0.3806% of total shares, with a total expenditure of 1,949,402.82 CNY[35] Cash Flow and Investments - Cash flow from operating activities for the first nine months of 2022 was CNY 9,041,301, a decrease of 48% from CNY 17,338,376 in 2021[57] - Total cash and cash equivalents at the end of Q3 2022 amounted to CNY 75,311,962, up from CNY 19,519,772 at the end of Q3 2021[58] - The company raised CNY 136,750,000 through investment in the first nine months of 2022[58] - Cash outflow from investing activities totaled $79,898,275.92, significantly higher than $25,126,878.71 in the prior period[60] - Cash used for the acquisition of fixed assets was $79,598,275.92, compared to $23,926,878.71, indicating a significant increase in capital expenditures[60] Government Support and Subsidies - The company received a government listing reward of CNY 1,500,000, contributing to an increase in other income[19] - The company received government subsidies closely related to its business totaling 5,194,733.78 CNY[22] Research and Development - Research and development expenses for Q3 2022 were ¥2,978,783.04, compared to ¥2,287,664.89 in Q3 2021, showing an increase of approximately 30.2% year-over-year[50] - Research and development expenses for the first nine months of 2022 totaled CNY 7,162,009, an increase of 10% compared to CNY 6,484,226 in 2021[53] Inventory and Contract Liabilities - Inventory increased by 30.98% to CNY 2,878,000 compared to the end of the previous year due to market demand[17] - The company reported a 389.71% increase in contract liabilities, attributed to new product offerings and advance payments from direct sales customers[18] - Inventory rose to CNY 28,685,144.99 as of September 30, 2022, compared to CNY 21,900,686.36 on December 31, 2021, indicating an increase of about 30.9%[41] Legal and Financial Commitments - The company has no outstanding commitments or overdue obligations related to disclosed commitments during the reporting period[36] - There were no significant legal disputes or external guarantees during the reporting period[30] - The company has cleared its bank loans and does not have any assets under mortgage or pledge as of the reporting period end[37]

Company Overview - Shanxi Dayu Biological received approval from the China Securities Regulatory Commission for public offering of shares on April 21, 2022, and successfully listed on the Beijing Stock Exchange on May 18, 2022[5]. - The company was awarded the "Enterprise Technology Innovation Award" by the Shanxi Provincial Government for the year 2021 on January 25, 2022[5]. - The company operates primarily in the animal husbandry sector, which is susceptible to significant risks from animal epidemics and natural disasters, potentially impacting sales of feed and feed additives[12]. - The company has been recognized as a high-tech enterprise since December 2016, benefiting from a reduced corporate income tax rate of 15% and tax deductions for eligible R&D expenses[13]. Financial Performance - The company's operating revenue for the period was CNY 59,399,772.91, a decrease of 23.44% compared to the same period last year[24]. - The net profit attributable to shareholders was CNY 7,844,216.36, down 31.51% year-on-year[24]. - The total assets increased by 37.49% to CNY 407,670,582.09 compared to the end of the previous year[25]. - The total liabilities decreased by 34.31% to CNY 54,685,259.88, indicating improved financial stability[25]. - The company reported a basic earnings per share of CNY 0.1805, a decline of 35.44% from the previous year[24]. - The net cash flow from operating activities was CNY 2,112,318.87, down 88.34% year-on-year[26]. - The company has a debt-to-asset ratio of 13.41%, significantly lower than the previous year's 28.08%[25]. Market Risks and Challenges - The cyclical nature of the pig farming industry may lead to fluctuations in demand for the company's products, particularly if pig prices continue to decline[12]. - The company relies heavily on a distribution model, with a significant number of distributors across various provinces, which poses risks if relationships with these distributors are not maintained[13]. - The ongoing uncertainty surrounding the COVID-19 pandemic may pose additional risks to the company's operations and market stability[13]. - The company faces risks related to potential changes in tax policies that could affect its profitability, particularly regarding VAT exemptions on certain feed products[13]. Product Development and R&D - The company’s product development focuses on creating nutritional solutions tailored to different growth stages of animals, which is essential for maintaining market competitiveness[13]. - The company has been focusing on the research and development of feed additives, including micro-ecological preparations and feed enzymes[30]. - The company has launched several micro-ecological preparation products, expanding its business into feed and veterinary medicine[30]. - The company aims to enhance its research and development capabilities to keep pace with market demands and maintain product competitiveness[70]. Shareholder and Governance Commitments - The company has established a governance structure to ensure the interests of minority shareholders are protected against potential control risks by major shareholders[73]. - The company has committed to avoiding any actions that could harm the interests of minority shareholders, including the misuse of funds[81]. - The company has reported no significant related party transactions during the reporting period, ensuring transparency in its financial dealings[76]. - The company will ensure that any income from violations of commitments will be returned to the company within 5 days[85]. Stock Issuance and Repurchase Plans - The company issued 15,000,000 shares at a price of 10.00 RMB per share, raising a total of 150,000,000 RMB during the reporting period[127]. - The company plans to implement measures to stabilize its stock price within three years of its public offering, including potential share buybacks by its actual controllers[89]. - The company will continue to repurchase shares if the stabilization measures do not meet the required conditions, with a maximum limit of 2% of the total capital within 12 months[92]. - The company has committed to not selling any shares acquired through the repurchase plan for 6 months after completion[94]. Profit Distribution Policy - The company emphasizes the importance of a stable and scientific profit distribution policy, ensuring continuity and stability in profit allocation[98]. - The company plans to prioritize cash dividends, with the cash dividend amount being the post-tax figure[99]. - The company will distribute at least 10% of the annual distributable profit in cash dividends, and the cumulative cash dividends over the last three years should not be less than 30% of the average annual distributable profit[101]. - The company will consider the opinions of independent directors and minority shareholders during the decision-making process for profit distribution policies[99]. Compliance and Regulatory Commitments - The company is committed to fulfilling its obligations regarding the public issuance of stocks to unspecified qualified investors, with strict adherence to relevant commitments made during the listing process on the Beijing Stock Exchange[102]. - The company guarantees that if it fails to fulfill its commitments, it will compensate investors for any losses incurred during the issuance and trading of securities[103]. - The company will publicly disclose the specific reasons for any failure to meet commitments in designated publications and apologize to shareholders and the public[104]. - The commitments made by the company and its executives are subject to supervision by regulatory bodies and the public[104]. Financial Position and Assets - The total value of restricted assets is 24,049,511.52 yuan, accounting for 5.90% of total assets[111]. - The largest shareholder, Yan Heping, holds 26,623,000 shares, representing 47.58% of total shares[119]. - The proportion of unrestricted shares increased from 11.28% to 29.70% after the issuance of new shares[115]. - The company reported a total of 181,879,396.30 CNY in current assets as of June 30, 2022, compared to 86,677,798.07 CNY at the end of 2021, indicating a significant increase[147].